Resistance to Autolysis in Vancomycin-Selected Staphylococcus aureus Isolates Precedes Vancomycin-Intermediate Resistance

Vancomycin Resistance in Staphylococcus aureus Strains

Vancomycin Resistance in Staphylococcus aureus


The evolution of Staphylococcus aureus during the modern antibiotic era has been delineated by distinct strain emergence events, many of which include acquisition of antibiotic resistance. The relative high burden of methicillin-resistant S. aureus (MRSA) in healthcare and community settings is a major concern worldwide. Vancomycin, a glycopeptide antibiotic that inhibits cell wall biosynthesis...

Vancomycin resistance in Staphylococcus aureus.

Vancomycin resistance in enterococci, predominantly Enterococcus faecium, developed in the latter half of the 1980s, and the long anticipated development of vancomycin resistance in Staphylococcus aureus has now occurred. A number of vancomycin-intermediate strains have been described, and these strains have abnormal, thickened cell walls in the presence of vancomycin. Two mechanisms of resista...

Prevalence of Vancomycin Resistance in Methicillin-Resistant Staphylococcus Aureus

Background & Aims: Staphylococcus aureus is one of the most common pathogens in nosocomial infections. Vancomycin is the most important therapeutic drug of choice for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) strains. Therefore, vancomycin-resistant Staphylococcus aureus (VRSA) or vancomycin-intermediate Staphylococcus aureus (VISA) strains are warning...

Daptomycin Resistance in Vancomycin-Intermediate Staphylococcus Aureus Isolate

We describe a patient with methicillin-resistant Staphylococcus aureus (MRSA) who developed resistance to daptomycin, a new cyclic lipopeptide recently approved for the treatment of infections by gram-positive organisms. Development of resistance to daptomycin during prolonged use may occur with MRSA bacteremia